Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 7;14(1):180.
doi: 10.1186/s12920-021-01029-3.

The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer

Affiliations

The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer

Soheila Delgir et al. BMC Med Genomics. .

Abstract

Background: Breast cancer (BC) is the most invasive cancer with different subtypes that its metabolism is unique compared with normal cells. Glutamine is considered critical nutrition that many cancer cells, particularly BC cells, are dependent on it for growth and proliferation. Therefore, targeting glutamine metabolism, especially enzymes that are related to this pathway, can be beneficial to design anti-cancer agents. Recent evidence has shown that microRNAs (miRNAs), with a short length and single-strand properties, play a prominent role in regulating the genes related to glutamine metabolism, which may control the development of cancer.

Methods: In silico analysis confirmed that miR-513c and miR-3163 might be involved in glutamine metabolism. The expression level of these two miRNAs was evaluated in eighty BC tissues and normal adjacent tissues. Furthermore, GSE38167, GSE38867, GSE42128, GSE45666, and GSE53179 were employed from gene expression omnibus (GEO). The Limma package was utilized to identify differentially expressed miRNAs (DEMs) of mentioned datasets to evaluate miR-513c and miR-3163 expression. Further, in silico analysis was utilized to predict the potential biological processes and molecular pathways of miR-513c and miR-3163, based on their target genes.

Results: In silico studies revealed top categories of biological processes and cellular pathways that might play a critical role in metabolism reprogramming and cancer development and were target genes for miR-513c and miR-3163. The current study showed that miR-513c (p value = 0.02062 and FC = - 2.3801) and miR-3163 (p value = 0.02034 and FC = - 2.3792) were downregulated in tumor tissues compared to normal adjacent tissues. The analysis of GEO microarray datasets showed that miR-513c was downregulated in GSE38167, GSE38867, GSE42128, GSE45666 and GSE53179, whereas there was a significant downregulation of miR-3163 in only two studies, including GSE38867 and GSE42128 that they were in accordance with our experimental results. Furthermore, the subgroup analysis did not show any substantial relationship between expression levels of these two miRNAs and factors such as age, family history of cancer, and abortion history.

Conclusion: MiR-513c and miR-3163 were downregulated in BC tissues, which might serve as tumor suppressors. They are suggested as potential therapeutic targets for patients with BC.

Keywords: Breast cancer; Fold change; Glutaminase; Glutamine metabolism; MicroRNA; miR-3163; miR-513c.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
The expression of miRNAs in tumor tissues and normal adjacent tissues. a The expression of miR-513c in tumor tissues and normal adjacent tissues. b The expression of miR-3163 in tumor tissues and normal adjacent tissues. In both figures, vertical axis, center line, and error bars represent ΔCTs values, median, and interquartile range, respectively
Fig. 2
Fig. 2
The curve analysis of both MiR-3163 (a) and MiR-513c (b) with AUCs (0.61 and 0.60, respectively)
Fig. 3
Fig. 3
The correlation of miR-513c expression level with age, abortion history, and cancer family history. a LFC-miR-513c in patients with cancer family history and without cancer family history (p value = 0.0525). b LFC-miR-513c in patients with abortion history and without abortion history (p value = 0.7713). c LFC-miR-513c in patients with age ≥ 50 and < 50 (p value = 0.6758). In three figures, vertical axis, center line, and error bars represent LFC (i.e., base 2 logarithm of FC), median, and interquartile range, respectively
Fig. 4
Fig. 4
The correlation of miR-3163 expression level with age, abortion history, and cancer family history. a LFC-miR-3163 in patients with cancer family history and without cancer family history (p value = 0.1208). b LFC-miR-3163 in patients with abortion history and without abortion history (p value = 0.5634). c LFC-miR-3163 in patients with age < 50 and ≥ 50 (p value = 0.3805). In three figures, vertical axis, center line, and error bars represent LFC (i.e., base 2 logarithm of FC), median, and interquartile range, respectively
Fig. 5
Fig. 5
Overall survival analysis of miR-513c-5p in BC from related datasets
Fig. 6
Fig. 6
Overall survival analysis of miR-3163 in BC from related datasets
Fig. 7
Fig. 7
The interaction between miR-513c-5p and its target genes
Fig. 8
Fig. 8
The interaction between miR-3163 and its target genes

Similar articles

Cited by

References

    1. Zare M, et al. Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J Cell Physiol. 2018;233(5):3729–3744. doi: 10.1002/jcp.26116. - DOI - PubMed
    1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: incidence and survival across European countries. Breast Care. 2019;14(6):344–353. doi: 10.1159/000503219. - DOI - PMC - PubMed
    1. Cardoso F, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi: 10.1093/annonc/mdz173. - DOI - PubMed
    1. Baradaran B, Hajiasgharzadeh K. Breast cancer among young women in Iran. Int J Women’s Health Reprod Sci. 2019;7(2):140. doi: 10.15296/ijwhr.2019.23. - DOI